May 20, 2014 – Dr. L'Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research ("Assises Nationales de la Recherche en Biomatériaux"; Autrans, France).
May 5, 2014 - Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco.  Program details can be found here.
April 27, 2014 – Dr. L'Heureux to present recent results regarding the use of "Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications" at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 - Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L'Heureux to speak at the INSERM Workshop #226 "3D cell culture bridges the gap between cell culture and live tissue" (Bordeaux, France).
March 14, 2014 - Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School  (Shanghai, China). 
October 7, 2013 - Results from the "First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access" are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 - Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report.  In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies.  See the full length manuscript in Regenerative Medicine here.
 
CLINICAL TRIALS

AV Access for Hemodialysis: Cytograft has clinical trials ongoing in both Europe and South America. The autologous version of the graft has a commercialization permit and can be sold in Germany. Clinical results from Cytograft’s lead product, the Lifeline™ graft for hemodialysis access have been reported in both the New England Journal of Medicine and the Lancet.

Lower Limb Bypass for Critical Limb Ischemia: The Lifeline™ graft will soon be available to a select cohort of patients suffering from critical limb ischemia that have been targeted for amputation. The Lifeline™ graft, coupled with cell injections into the lower limb will be available for 'no option' patients in an attempt to delay or even avoid amputation. Patients with severe critical limb ischemia that are interested in enrolling in this study can email here for more information: CLI_clinicaltrials@cytograft.com.

Updates will be posted on this website and will also be available on www.clinicaltrials.gov.